Cargando…
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
The broadly neutralizing antibody (bnAb) VRC01 is being evaluated for its efficacy to prevent HIV-1 infection in the Antibody Mediated Prevention (AMP) trials. A secondary objective of AMP utilizes sieve analysis to investigate how VRC01 prevention efficacy (PE) varies with HIV-1 envelope (Env) amin...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459550/ https://www.ncbi.nlm.nih.gov/pubmed/30933973 http://dx.doi.org/10.1371/journal.pcbi.1006952 |
_version_ | 1783410201457590272 |
---|---|
author | Magaret, Craig A. Benkeser, David C. Williamson, Brian D. Borate, Bhavesh R. Carpp, Lindsay N. Georgiev, Ivelin S. Setliff, Ian Dingens, Adam S. Simon, Noah Carone, Marco Simpkins, Christopher Montefiori, David Alter, Galit Yu, Wen-Han Juraska, Michal Edlefsen, Paul T. Karuna, Shelly Mgodi, Nyaradzo M. Edugupanti, Srilatha Gilbert, Peter B. |
author_facet | Magaret, Craig A. Benkeser, David C. Williamson, Brian D. Borate, Bhavesh R. Carpp, Lindsay N. Georgiev, Ivelin S. Setliff, Ian Dingens, Adam S. Simon, Noah Carone, Marco Simpkins, Christopher Montefiori, David Alter, Galit Yu, Wen-Han Juraska, Michal Edlefsen, Paul T. Karuna, Shelly Mgodi, Nyaradzo M. Edugupanti, Srilatha Gilbert, Peter B. |
author_sort | Magaret, Craig A. |
collection | PubMed |
description | The broadly neutralizing antibody (bnAb) VRC01 is being evaluated for its efficacy to prevent HIV-1 infection in the Antibody Mediated Prevention (AMP) trials. A secondary objective of AMP utilizes sieve analysis to investigate how VRC01 prevention efficacy (PE) varies with HIV-1 envelope (Env) amino acid (AA) sequence features. An exhaustive analysis that tests how PE depends on every AA feature with sufficient variation would have low statistical power. To design an adequately powered primary sieve analysis for AMP, we modeled VRC01 neutralization as a function of Env AA sequence features of 611 HIV-1 gp160 pseudoviruses from the CATNAP database, with objectives: (1) to develop models that best predict the neutralization readouts; and (2) to rank AA features by their predictive importance with classification and regression methods. The dataset was split in half, and machine learning algorithms were applied to each half, each analyzed separately using cross-validation and hold-out validation. We selected Super Learner, a nonparametric ensemble-based cross-validated learning method, for advancement to the primary sieve analysis. This method predicted the dichotomous resistance outcome of whether the IC(50) neutralization titer of VRC01 for a given Env pseudovirus is right-censored (indicating resistance) with an average validated AUC of 0.868 across the two hold-out datasets. Quantitative log IC(50) was predicted with an average validated R(2) of 0.355. Features predicting neutralization sensitivity or resistance included 26 surface-accessible residues in the VRC01 and CD4 binding footprints, the length of gp120, the length of Env, the number of cysteines in gp120, the number of cysteines in Env, and 4 potential N-linked glycosylation sites; the top features will be advanced to the primary sieve analysis. This modeling framework may also inform the study of VRC01 in the treatment of HIV-infected persons. |
format | Online Article Text |
id | pubmed-6459550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-64595502019-05-03 Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features Magaret, Craig A. Benkeser, David C. Williamson, Brian D. Borate, Bhavesh R. Carpp, Lindsay N. Georgiev, Ivelin S. Setliff, Ian Dingens, Adam S. Simon, Noah Carone, Marco Simpkins, Christopher Montefiori, David Alter, Galit Yu, Wen-Han Juraska, Michal Edlefsen, Paul T. Karuna, Shelly Mgodi, Nyaradzo M. Edugupanti, Srilatha Gilbert, Peter B. PLoS Comput Biol Research Article The broadly neutralizing antibody (bnAb) VRC01 is being evaluated for its efficacy to prevent HIV-1 infection in the Antibody Mediated Prevention (AMP) trials. A secondary objective of AMP utilizes sieve analysis to investigate how VRC01 prevention efficacy (PE) varies with HIV-1 envelope (Env) amino acid (AA) sequence features. An exhaustive analysis that tests how PE depends on every AA feature with sufficient variation would have low statistical power. To design an adequately powered primary sieve analysis for AMP, we modeled VRC01 neutralization as a function of Env AA sequence features of 611 HIV-1 gp160 pseudoviruses from the CATNAP database, with objectives: (1) to develop models that best predict the neutralization readouts; and (2) to rank AA features by their predictive importance with classification and regression methods. The dataset was split in half, and machine learning algorithms were applied to each half, each analyzed separately using cross-validation and hold-out validation. We selected Super Learner, a nonparametric ensemble-based cross-validated learning method, for advancement to the primary sieve analysis. This method predicted the dichotomous resistance outcome of whether the IC(50) neutralization titer of VRC01 for a given Env pseudovirus is right-censored (indicating resistance) with an average validated AUC of 0.868 across the two hold-out datasets. Quantitative log IC(50) was predicted with an average validated R(2) of 0.355. Features predicting neutralization sensitivity or resistance included 26 surface-accessible residues in the VRC01 and CD4 binding footprints, the length of gp120, the length of Env, the number of cysteines in gp120, the number of cysteines in Env, and 4 potential N-linked glycosylation sites; the top features will be advanced to the primary sieve analysis. This modeling framework may also inform the study of VRC01 in the treatment of HIV-infected persons. Public Library of Science 2019-04-01 /pmc/articles/PMC6459550/ /pubmed/30933973 http://dx.doi.org/10.1371/journal.pcbi.1006952 Text en © 2019 Magaret et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Magaret, Craig A. Benkeser, David C. Williamson, Brian D. Borate, Bhavesh R. Carpp, Lindsay N. Georgiev, Ivelin S. Setliff, Ian Dingens, Adam S. Simon, Noah Carone, Marco Simpkins, Christopher Montefiori, David Alter, Galit Yu, Wen-Han Juraska, Michal Edlefsen, Paul T. Karuna, Shelly Mgodi, Nyaradzo M. Edugupanti, Srilatha Gilbert, Peter B. Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features |
title | Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features |
title_full | Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features |
title_fullStr | Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features |
title_full_unstemmed | Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features |
title_short | Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features |
title_sort | prediction of vrc01 neutralization sensitivity by hiv-1 gp160 sequence features |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459550/ https://www.ncbi.nlm.nih.gov/pubmed/30933973 http://dx.doi.org/10.1371/journal.pcbi.1006952 |
work_keys_str_mv | AT magaretcraiga predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT benkeserdavidc predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT williamsonbriand predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT boratebhaveshr predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT carpplindsayn predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT georgievivelins predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT setliffian predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT dingensadams predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT simonnoah predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT caronemarco predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT simpkinschristopher predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT montefioridavid predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT altergalit predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT yuwenhan predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT juraskamichal predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT edlefsenpault predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT karunashelly predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT mgodinyaradzom predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT edugupantisrilatha predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures AT gilbertpeterb predictionofvrc01neutralizationsensitivitybyhiv1gp160sequencefeatures |